Drug Search Results
More Filters [+]

Galsulfase

Alternative Names: galsulfase, naglazyme
Latest Update: 2024-08-22
Latest Update Note: News Article

Product Description

GALSULFASE is an enzyme replacement. It is used to treat the symptoms of mucopolysaccharidosis VI (also known as MPS VI or Maroteaux-Lamy syndrome). (Sourced from: https://my.clevelandclinic.org/health/drugs/19237-galsulfase-injection)

Mechanisms of Action: Glycosaminoglycan Catabolizer

Novel Mechanism: No

Modality: N/A

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Malaysia | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Russia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Ukraine | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Galsulfase

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events